THERAPY DOSSIER · th-05ac250fe15e

Mexicor (ethylmethylhydroxypyridine succinate)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL6068558 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Emicidin; Emoxypine succinate; Methylethylpiridinol succinate; Mexicor; Mexidol; Mexiprim
Note: Not recorded

Clinical trials 9

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06437639 ↗PHASE4completed

Efficacy and Safety of Mexidol Sequential Therapy in Primary Open-angle Glaucoma

Primary Open-Angle Glaucoma

Enrolment: 80 · Results not recorded

NCT07575984 ↗PHASE4recruiting

Mexidol Solution and Mexidol FORTE 250 in Treatment of Ischaemic Stroke in Hyperacute and Acute Periods

Ischemic Stroke

Enrolment: 120 · Results not recorded

NCT06221826 ↗PHASE4completed

Modulating Effect of MEXIDOL as Adjuvant Stimulant in Rehabilitation of Patients With Acute Cerebral Failure

Ischemic Stroke, Acute

Enrolment: 60 · Results not recorded

NCT07700615 ↗PHASE4completed

Mexidol as Add-On to Standard Therapy in Older Adults With Vascular Cognitive Impairment, No Dementia

Vascular Cognitive Impairment no Dementia

Enrolment: 120 · Results not recorded

NCT06834490 ↗PHASE3completed

Sequential Therapy With Mexidol Solution and Mexidol FORTE 250 in Patients With Chronic Cerebral Ischaemia (MEMO)

Chronic Cerebral Ischemia

Enrolment: 318 · Results not recorded

NCT06854601 ↗PHASE3completed

Mexidol Film-coated Tablets 125 mg in Treatment of ADHD in Children Aged 6-12 Years (MEGA)

Attention Deficit Hyperactivity Disorder · Anxiety Disorders

Enrolment: 333 · Results not recorded

NCT06437626 ↗PHASE3completed

Mexidol (Ethylmethylhydroxypyridine Succinate) in Sequential Treatment of Acute and Early Recovery Periods of Ischaemic Stroke

Ischemic Stroke

Enrolment: 304 · Results not recorded

NCT02793687 ↗PHASE3completed

Mexidol in Long-term Sequential Treatment of Acute and Early Recovery Periods of Hemispheric Ischaemic Stroke (EPICA)

Ischemic Stroke

Enrolment: 150 · Results not recorded

NCT06903156 ↗PHASE2completed

Efficacy and Safety of Different Dosages in Sequential Therapy With Mexidol in Primary Open-angle Glaucoma

Primary Open-Angle Glaucoma

Enrolment: 102 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29119396 ↗2017Reported benefit

Functional and Biochemical Parameters of Erythrocytes during Mexicor Treatment in Posttraumatic Period after Experimental Blood Loss and Combined Traumatic Brain Injury.

RatTBIUnspecifiedFemale8 mg/kg body weight per dayAdministered during the post-traumatic period

Model: Combined traumatic brain injury and acute blood loss in rats, assessed through the post-traumatic period

Mexicor increased erythrocyte electrophoretic mobility and 2,3-diphosphoglycerate concentration and lowered malondialdehyde content after combined traumatic brain injury and acute blood loss. These changes were associated with improved haemodynamics and blood oxygen transport. The effects were most…

Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…